Sade Sunshine Dental Completes Series A Financing of Several Hundred Million RMB to Accelerate Nationwide Expansion
VCBeat (WeChat ID: vcbeat) has learned that China’s leading premium dental chain, Suncare Dental Group, recently announced the completion of its Series A financing round, raising hundreds of millions of RMB. The round was co-led by Qiming Venture Partners and Sunshine Ronghui Capital, with iCapital serving as the exclusive financial advisor for the transaction.
The success of this financing round underscores the strong endorsement by China’s top-tier star funds for premium dental chain enterprises that feature specialized niche clinical services, world-class service quality and medical technology, distinguished physician teams and academic leadership, as well as solid customer reputation and brand value. It also highlights Cai Capital’s dominant position in investment and financing within the healthcare services sector and the broader health industry.
Sunny Dental was established in 2007 in Beijing by Professor Zhou Yanheng, a doctoral supervisor at Peking University School of Stomatology, President of the Asian Pacific Orthodontic Society, and Executive Committee Member of the World Federation of Orthodontists.
The company’s team of dentists comprises over 100 master’s and doctoral graduates in stomatology from prestigious institutions such as Peking University Health Science Center, West China School of Stomatology, Shanghai Ninth People’s Hospital, and the Fourth Military Medical University. Among them, more than 30 dentists hold master’s or doctoral degrees specifically from Peking University School of Stomatology. The number of full-time dentists with master’s or doctoral degrees from top-tier universities ranks first among all private dental chains in China.
Data shows that the company’s business model, featuring orthodontics as its core specialty, has achieved relatively superior unit economics for individual stores within the dental industry. Its revenue per square meter, labor productivity, and output per dental chair far exceed industry averages, with all mature stores achieving profitability. In terms of technological and clinical expertise, Saide Sunshine Oral Care operates the Invisalign China Center—the only authorized facility in Greater China with the most advanced infrastructure and comprehensive technical capabilities for Invisalign.
The company has cumulatively treated nearly 160,000 cases across various dental specialties, including malocclusion. It possesses the largest number of internationally recognized outstanding orthodontic cases in China (selected for the International Gallery case database) and is the first Chinese orthodontic practice to deliver a special lecture on Invisalign at an international conference. Furthermore, it has been designated as a referral center for complex orthodontic cases by numerous large public hospitals nationwide.
In addition to its team of physicians and technological advantages, the company has established an integrated platform for medical practice, education, and research—the Saide Sunshine Oral Clinical Research Institute—and partnered with Peking University to launch the Peking University Health Science Center Saide Sunshine Medical Development Program, thereby building its own talent development system.
The company currently operates 18 dental clinics and one specialized dental hospital in Beijing, Shenzhen, Shanghai, Xiamen, Guangzhou, and other cities, with a total outpatient area of 18,000 square meters. Following this round of financing, Saide Sunshine will accelerate its expansion and layout across China, becoming one of the leading dental chain groups in the country.
Commenting on the success of this round of financing, Professor Zhou Yanheng, Founder and Chairman of Sailide Sunshine Group, stated, “Named in homage to ‘Mr. Democracy’ and ‘Mr. Science,’ Sailide Sunshine Oral Care has carried the legacy of Peking University since its establishment in Beijing in 2007. Over the past 13 years of steadfast progress, Sailide Sunshine Oral Care has upheld the Peking University spirit of virtue and scholarship, pursued diversified development across medical practice, education, research, and prevention, and remained committed to the core medical principle of putting patients first. We have strived to make Sailide Sunshine Oral Care distinctive, excellent, refined, cutting-edge, and robust. Meanwhile, the Group has actively responded to and implemented national policies such as the ‘Healthy China 2030’ Planning Outline, working to enhance public awareness of oral health care and provide more professional oral medical services to a broader population. With patients at heart and dedicated to advancing orthodontics, we have become a leader in Invisalign clear aligner technology both in China and globally. We have not only earned recognition from patients at home and abroad but also received widespread acclaim from our peers. Sailide Sunshine will join hands with orthodontic colleagues and partners across China to witness the rapid growth of China’s private oral healthcare sector and jointly explore the boundless possibilities of clear aligner technology!”
Gao Jinda, Executive Director at Qiming Venture Partners, which participated in this round of financing, stated, “We are highly optimistic about the development prospects of the dental healthcare industry, particularly the orthodontics segment, which is experiencing rapid growth driven by consumers’ increasing pursuit of aesthetic improvement. Under the leadership of Professor Zhou Yanheng, Saide Sunshine has assembled China’s most professional team of orthodontists, boasts first-class orthodontic treatment technologies, and enjoys a strong customer reputation, while having accumulated extensive experience in chain operations over many years. We are pleased to have the opportunity to participate in the company’s current funding round. High-quality domestic medical service brands are scarce, and we hope this financing will support the company’s clinic expansion, strengthen its management systems and brand building, and enable it to provide high-quality, professional dental healthcare services to more patients in the future.”
Huang Shengxuan, Managing Director of Sunshine Ronghui Capital Investment Management Co., Ltd., stated, “As a key segment in consumer healthcare, dental chain clinics have always been a strategic focus for Sunshine Ronghui Capital within the medical services industry. We are delighted to enter into a strategic partnership with Saide Sunshine Oral Care. As the only nationwide dental chain in the industry centered on orthodontics, Saide Sunshine has established an academic stronghold, high-quality medical care, and strong brand value through its ‘dream team’ of orthodontic experts led by Professor Zhou Yanheng. As an insurance-backed fund, our core investment philosophy integrates insurance with healthcare. Sunshine Ronghui will actively promote business synergy between Saide Sunshine and Sunshine Insurance Group, empowering Saide Sunshine through channel customer resources, collaborative health insurance products, and other initiatives, serving as a long-term partner and solid backing for its corporate development.”
Li Gang, Partner at China Renaissance Capital, the exclusive financial advisor for this transaction, stated: “China’s oral healthcare market is vast in scale. Orthodontics, the fastest-growing segment within oral healthcare services, is characterized by its broad patient coverage and high technical sophistication. As the only premium dental chain in China specializing primarily in orthodontics, Sunny Dental has leveraged the profound academic heritage and medical legacy of Peking University Health Science Center. Over more than a decade of development, it has grown into the leading national orthodontic dental chain. China Renaissance Capital is honored to have assisted Sunny Dental in completing this financing round and is confident in supporting the company’s growth into a leading enterprise in China’s oral healthcare industry.”
About Qiming Venture Partners
Qiming Venture Partners was founded in 2006 and has established offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages seven U.S. dollar funds and five RMB funds, with total assets under management exceeding USD 4 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as TMT and Healthcare.
Since its inception, Qiming Venture Partners has earned widespread recognition from limited partners globally, including in China, for its outstanding investment performance, becoming the preferred venture capital firm for entrepreneurs. Across multiple authoritative rankings, Qiming Venture Partners has emerged as a leading fund in China’s venture capital industry.
About Sunshine Hui Capital
Sunshine Ronghui Capital Investment Management Co., Ltd. was established in January 2015 as one of the first pilot units for insurance private equity funds approved by the China Insurance Regulatory Commission (CIRC), with assets under management reaching RMB 18 billion. Upholding the corporate vision of “Making Life Better,” and guided by its mission to “create value, earn trust, allocate resources to the most valuable enterprises, and gain investors’ confidence through superior returns,” Sunshine Ronghui Capital has actively deployed investments across healthcare, emerging industries, new consumption, industrial M&A, and real estate. The firm invests in enterprises through diverse approaches—including venture support, strategic investment, financial investment, mergers and acquisitions, corporate restructuring, and cross-border investment—to comprehensively enhance enterprise value and support healthy, sustainable growth. To date, Sunshine Ronghui Capital has invested in numerous companies in the fields of healthcare, pharmaceuticals, internet, and innovative financial services.
About China Renaissance
China Renaissance was founded in 2000 and is China’s leading new-economy investment bank focused on the three major sectors of healthcare, consumer, and TMT. Headquartered in Beijing, the firm maintains branch offices in Shanghai, Los Angeles, and San Francisco, and holds a U.S. securities business license.
From 2017 to 2019, iCapital participated in financing and M&A transactions with a total value exceeding RMB 100 billion. In addition to its investment banking services, iCapital entered the asset management business in 2014 and is currently managing one RMB fund and one USD fund.
In the healthcare industry, China Renaissance boasts the largest, most professional, and most comprehensively integrated investment banking team in the sector, along with a firmly established position of strong market leadership. For three consecutive years, it has ranked as the new-economy investment bank with the highest number of healthcare industry transactions in China.
Related Reading: